| Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness K Desai, SL Sansom, ML Ackers, SR Stewart, HI Hall, DJ Hu, R Sanders, ... Aids 22 (14), 1829-1839, 2008 | 194 | 2008 |
| Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings S Soorapanth, S Sansom, M Bulterys, M Besser, G Theron, MG Fowler JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (2), 213-221, 2006 | 57 | 2006 |
| Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis VS Prabhu, PG Farnham, AB Hutchinson, S Soorapanth, JD Heffelfinger, ... PLoS One 6 (5), e19936, 2011 | 47 | 2011 |
| A Lagrangian relaxation based approach to schedule asset overhaul and repair services PB Luh, D Yu, S Soorapanth, AI Khibnik, R Rajamani IEEE Transactions on Automation Science and Engineering 2 (2), 145-157, 2005 | 44 | 2005 |
| Infection transmission system models for microbial risk assessment SE Chick, JS Koopman, S Soorapanth, ME Brown Science of the Total Environment 274 (1-3), 197-207, 2001 | 34 | 2001 |
| Inferring infection transmission parameters that influence water treatment decisions SE Chick, S Soorapanth, JS Koopman Management Science 49 (7), 920-935, 2003 | 30 | 2003 |
| Updated estimates of healthcare utilization and costs among perinatally HIV-infected children SL Sansom, JE Anderson, PG Farnham, K Dominguez, S Soorapanth, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 41 (4), 521-526, 2006 | 25 | 2006 |
| 18 MICROBIAL RISK ASSESSMENT FOR DRINKING WATER SE Chick, S Soorapanth, JS Koopman Operations Research and Health Care: A Handbook of Methods and Applications …, 2004 | 9 | 2004 |
| Assessing the value of modelling and simulation in health care: An example based on increasing access to stroke treatment S Soorapanth, T Young Journal of the Operational Research Society 70 (2), 226-236, 2019 | 8 | 2019 |
| Evaluating the financial impact of modeling and simulation in healthcare: Proposed framework with a case study S Soorapanth, T Young 2015 Winter Simulation Conference (WSC), 1492-1502, 2015 | 8 | 2015 |
| The costs and value of modelling-based design in healthcare delivery: Five case studies from the US T Young, S Soorapanth, J Wilkerson, L Millburg, T Roberts, ... Health Systems 9 (3), 253-262, 2020 | 7 | 2020 |
| Scheduling asset overhaul and repair services PB Luh, S Soorapanth, DQ Yu, AI Khibnik Proceedings of the 2003 NSF Design, Service and Manufacturing Grantees and …, 2003 | 5 | 2003 |
| Simulation of stochastic infection transmission models designed to inform water treatment decisions S Soorapanth, SE Chick, JS Koopman Proceedings of the 13th European Simulation Symposium, 517-521, 2001 | 5 | 2001 |
| Systems, design and value-for-money in the NHS: mission impossible? T Young, A Morton, S Soorapanth Future Healthcare Journal 5 (3), 156, 2018 | 4 | 2018 |
| Cost-utility analysis of behavioral interventions for HIV-infected persons to reduce HIV transmission in the USA S Soorapanth, SE Chick Proceedings of the 2010 Winter Simulation Conference, 2433-2443, 2010 | 4 | 2010 |
| Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany A Brogan, S Soorapanth, V Donatz, A Hill, E Smets Value in Health 12 (7), A426, 2009 | 3 | 2009 |
| Microbial risk models designed to inform water treatment policy decisions S Soorapanth University of Michigan, 2002 | 3 | 2002 |
| Towards a framework for evaluating the costs and benefits of simulation modelling in healthcare S Soorapanth, T Eldabi, T Young Journal of the Operational Research Society, 1-10, 2022 | 2 | 2022 |
| Comparative cost-efficacy analysis of darunavir/r for first-line treatment of HIV infection in the United States S Soorapanth, A Brogan, J Mrus, E Smets Value in Health 12, A112, 2009 | 2 | 2009 |
| Comparative cost-efficacy analysis of darunavir/r and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in Germany [abstract PE19. 5/3] E Smets, M Stoll, A Hill, S Soorapanth, V Donatz, A Brogan 12th European AIDS Conference, 11-14, 2009 | 2 | 2009 |
